Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate to severe plaque psoriasis
https://doi.org/10.4081/dr.2024.9999
Accepted: 5 August 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Psoriasis is an inflammatory chronic disease of the skin typically located on the extensor surfaces of the body, and the trunk. Patients with psoriasis can often present multiple characteristics, such as lesions located in difficult-to-treat (DTT) areas or a high severity of the disease, which can negatively affect their quality of life. There is a lack of consensus in identifying the best therapy for these complex patient populations, especially after the failure of one or multiple lines of therapy. In this regard, we report a case series describing patients with psoriasis located in different DTT areas or presenting a high Psoriasis Area and Severity Index score at baseline and treated ineffectively with prior lines of therapy. Finally, patients achieved complete remission following therapy with tildrakizumab 200 mg (anti-IL-23p19), highlighting its potential efficacy in these patient populations.
Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers 2016;2,16082. DOI: https://doi.org/10.1038/nrdp.2016.82
Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA 2020;323,1945-60. DOI: https://doi.org/10.1001/jama.2020.4006
Bardazzi F, Viviani F, Filippi F, et al. The legs: An underestimated difficult-to-treat area of psoriasis. Dermatol Ther 2022;35,e15485. DOI: https://doi.org/10.1111/dth.15485
Hjuler KF, Iversen L, Rasmussen MK, et al. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol 2019;181,332-7. DOI: https://doi.org/10.1111/bjd.17689
Menter A, Bhutani T, Ehst B, et al. Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis. Dermatol Ther (Heidelb) 2022;12,1289-302. DOI: https://doi.org/10.1007/s13555-022-00746-6
Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. J Clin Med 2022;11. DOI: https://doi.org/10.3390/jcm11092631
Kowalewska B, Jankowiak B, Cybulski M, et al. Effect of Disease Severity on the Quality of Life and Sense of Stigmatization in Psoriatics. Clin Cosmet Investig Dermatol 2021;14,107-21. DOI: https://doi.org/10.2147/CCID.S286312
Seidl U, Pinter A, Wilsmann-Theis D, et al. Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care. Dermatol Ther 2022;35,e15193. DOI: https://doi.org/10.1111/dth.15193
Armstrong AW, Villanueva Quintero DG, Echeverria CM, et al. Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab. Am J Clin Dermatol 2016;17,691-9. DOI: https://doi.org/10.1007/s40257-016-0229-x
Reich K, Mrowietz U, Menter A, et al. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. J Eur Acad Dermatol Venereol 2021;35,2409-14. DOI: https://doi.org/10.1111/jdv.17520
Tildrakizumab. Summary of Product Characteristics.
Hu Y, Chen Z, Gong Y, et al. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis. Clin Drug Investig 2018;38,191-9. DOI: https://doi.org/10.1007/s40261-017-0603-3
Papp KA, Reich K, Blauvelt A, et al. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. J Eur Acad Dermatol Venereol 2019;33,1098-106. DOI: https://doi.org/10.1111/jdv.15400
Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol 2020;182,605-17. DOI: https://doi.org/10.1111/bjd.18232
Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 2019;394,831-9. DOI: https://doi.org/10.1016/S0140-6736(19)31773-8
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
